Fc receptor but not complement binding is important in antibody protection against HIV - PubMed (original) (raw)
. 2007 Sep 6;449(7158):101-4.
doi: 10.1038/nature06106.
Lars Hangartner, Meredith Hunter, Carin E G Havenith, Frank J Beurskens, Joost M Bakker, Caroline M S Lanigan, Gary Landucci, Donald N Forthal, Paul W H I Parren, Preston A Marx, Dennis R Burton
Affiliations
- PMID: 17805298
- DOI: 10.1038/nature06106
Fc receptor but not complement binding is important in antibody protection against HIV
Ann J Hessell et al. Nature. 2007.
Abstract
Most successful vaccines elicit neutralizing antibodies and this property is a high priority when developing an HIV vaccine. Indeed, passively administered neutralizing antibodies have been shown to protect against HIV challenge in some of the best available animal models. For example, antibodies given intravenously can protect macaques against intravenous or mucosal SHIV (an HIV/SIV chimaera) challenge and topically applied antibodies can protect macaques against vaginal SHIV challenge. However, the mechanism(s) by which neutralizing antibodies afford protection against HIV is not understood and, in particular, the role of antibody Fc-mediated effector functions is unclear. Here we report that there is a dramatic decrease in the ability of a broadly neutralizing antibody to protect macaques against SHIV challenge when Fc receptor and complement-binding activities are engineered out of the antibody. No loss of antibody protective activity is associated with the elimination of complement binding alone. Our in vivo results are consistent with in vitro assays indicating that interaction of Fc-receptor-bearing effector cells with antibody-complexed infected cells is important in reducing virus yield from infected cells. Overall, the data suggest the potential importance of activity against both infected cells and free virus for effective protection against HIV.
Comment in
- HIV/AIDS: allied responses.
Mascola JR. Mascola JR. Nature. 2007 Sep 6;449(7158):29-30. doi: 10.1038/449029a. Nature. 2007. PMID: 17805280 No abstract available.
Similar articles
- Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
Miyake A, Akagi T, Enose Y, Ueno M, Kawamura M, Horiuchi R, Hiraishi K, Adachi M, Serizawa T, Narayan O, Akashi M, Baba M, Hayami M. Miyake A, et al. J Med Virol. 2004 Jul;73(3):368-77. doi: 10.1002/jmv.20100. J Med Virol. 2004. PMID: 15170630 - Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG. Mascola JR, et al. Nat Med. 2000 Feb;6(2):207-10. doi: 10.1038/72318. Nat Med. 2000. PMID: 10655111 - HIV/AIDS: allied responses.
Mascola JR. Mascola JR. Nature. 2007 Sep 6;449(7158):29-30. doi: 10.1038/449029a. Nature. 2007. PMID: 17805280 No abstract available. - Humoral immunity to HIV, SIV, and SHIV.
Haigwood NL, Zolla-Pazner S. Haigwood NL, et al. AIDS. 1998;12 Suppl A:S121-32. AIDS. 1998. PMID: 9632993 Review. No abstract available. - Neutralization and enhancement of in vitro and in vivo HIV and simian immunodeficiency virus infections.
Robinson WE Jr, Mitchell WM. Robinson WE Jr, et al. AIDS. 1990;4 Suppl 1:S151-62. AIDS. 1990. PMID: 2152561 Review.
Cited by
- Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fcγ receptors during acute SHIVAD8-EO infection.
Dias J, Fabozzi G, Fourati S, Chen X, Liu C, Ambrozak DR, Ransier A, Laboune F, Hu J, Shi W, March K, Maximova AA, Schmidt SD, Samsel J, Talana CA, Ernste K, Ko SH, Lucas ME, Radecki PE, Boswell KL, Nishimura Y, Todd JP, Martin MA, Petrovas C, Boritz EA, Doria-Rose NA, Douek DC, Sékaly RP, Lifson JD, Asokan M, Gama L, Mascola JR, Pegu A, Koup RA. Dias J, et al. Nat Commun. 2024 Aug 29;15(1):7461. doi: 10.1038/s41467-024-51848-y. Nat Commun. 2024. PMID: 39198422 Free PMC article. - Activating FcγRs on monocytes are necessary for optimal Mayaro virus clearance.
Dunagan MM, Dábilla N, McNinch C, Brenchley JM, Dolan PT, Fox JM. Dunagan MM, et al. bioRxiv [Preprint]. 2024 Jul 24:2024.07.23.604823. doi: 10.1101/2024.07.23.604823. bioRxiv. 2024. PMID: 39149309 Free PMC article. Preprint. - The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity.
Marchitto L, Richard J, Prévost J, Tauzin A, Yang D, Chiu T, Chen HC, Díaz-Salinas MA, Nayrac M, Benlarbi M, Beaudoin-Bussières G, Anand SP, Dionne K, Bélanger É, Chatterjee D, Medjahed H, Bourassa C, Tolbert WD, Hahn BH, Munro JB, Pazgier M, Smith AB 3rd, Finzi A. Marchitto L, et al. bioRxiv [Preprint]. 2024 Jun 7:2024.06.07.597978. doi: 10.1101/2024.06.07.597978. bioRxiv. 2024. PMID: 38895270 Free PMC article. Updated. Preprint. - Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.
Nkumama IN, Ogwang R, Odera D, Musasia F, Mwai K, Nyamako L, Murungi L, Tuju J, Fürle K, Rosenkranz M, Kimathi R, Njuguna P, Hamaluba M, Kapulu MC, Frank R; CHMI-SIKA study team; Osier FHA. Nkumama IN, et al. Immunity. 2024 Jun 11;57(6):1215-1224.e6. doi: 10.1016/j.immuni.2024.05.001. Epub 2024 May 23. Immunity. 2024. PMID: 38788711 Free PMC article. - Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives.
Mahomed S. Mahomed S. Clin Microbiol Rev. 2024 Jun 13;37(2):e0015222. doi: 10.1128/cmr.00152-22. Epub 2024 Apr 30. Clin Microbiol Rev. 2024. PMID: 38687039 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical